1. Academic Validation
  2. Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors

Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors

  • ACS Med Chem Lett. 2020 May 1;11(6):1160-1167. doi: 10.1021/acsmedchemlett.0c00025.
Michael B Plewe 1 Nadezda V Sokolova 1 Vidyasagar Reddy Gantla 1 Eric R Brown 1 Shibani Naik 1 Alexandra Fetsko 1 Donald D Lorimer 2 3 David M Dranow 2 3 Hayden Smutney 2 4 Jameson Bullen 2 3 Rana Sidhu 2 4 Arshil Master 2 4 Junru Wang 2 4 E Adam Kallel 5 Lihong Zhang 6 Birte Kalveram 6 Alexander N Freiberg 6 6 Greg Henkel 1 Ken McCormack 1
Affiliations

Affiliations

  • 1 Arisan Therapeutics, 11189 Sorrento Valley Road, Suite 104, San Diego, California 92121, United States.
  • 2 Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, Washington 98105, United States.
  • 3 UCB Pharma, 7869 NE Day Road West, Bainbridge Island, Washington 98110, United States.
  • 4 UCB Pharma, 3 Preston Court, Bedford, Massachusetts 01730, United States.
  • 5 Victrix, 12631 Bendito Drive, San Diego, California 92128, United States.
  • 6 Department of Pathology andCenter for Biodefense and Emerging Infectious Diseases, The University of Texas Medical Branch, Galveston, Texas 77555, United States.
Abstract

We identified and explored the structure-activity-relationship (SAR) of an adamantane carboxamide chemical series of Ebola virus (EBOV) inhibitors. Selected analogs exhibited half-maximal inhibitory concentrations (EC50 values) of ∼10-15 nM in vesicular stomatitis virus (VSV) pseudotyped EBOV (pEBOV) infectivity assays, low hundred nanomolar EC50 activity against wild type EBOV, aqueous solubility >20 mg/mL, and attractive metabolic stability in human and nonhuman liver microsomes. X-ray cocrystallographic characterizations of a lead compound with the EBOV glycoprotein (GP) established the EBOV GP as a target for direct compound inhibitory activity and further provided relevant structural models that may assist in identifying optimized therapeutic candidates.

Figures
Products